These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36925722)

  • 21. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
    Cao Y; Song W; Wang L; Liu P; Yue C; Jian F; Yu Y; Yisimayi A; Wang P; Wang Y; Zhu Q; Deng J; Fu W; Yu L; Zhang N; Wang J; Xiao T; An R; Wang J; Liu L; Yang S; Niu X; Gu Q; Shao F; Hao X; Meng B; Gupta RK; Jin R; Wang Y; Xie XS; Wang X
    Cell Host Microbe; 2022 Nov; 30(11):1527-1539.e5. PubMed ID: 36270286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.
    Wang Y; Yan A; Song D; Dong C; Rao M; Gao Y; Qi R; Ma X; Wang Q; Xu H; Liu H; Han J; Duan M; Liu S; Yu X; Zong M; Feng J; Jiao J; Zhang H; Li M; Yu B; Wang Y; Meng F; Ni X; Li Y; Shen Z; Sun B; Shao X; Zhao H; Zhao Y; Li R; Zhang Y; Du G; Lu J; You C; Jiang H; Zhang L; Wang L; Dou C; Liu Z; Zhao J
    Cell Discov; 2023 Jan; 9(1):3. PubMed ID: 36609558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD.
    Li Q; Zhang M; Liang Z; Zhang L; Wu X; Yang C; An Y; Tong J; Liu S; Li T; Cui Q; Nie J; Wu J; Huang W; Wang Y
    MedComm (2020); 2022 Jun; 3(2):e130. PubMed ID: 35434713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant.
    Zhou Z; Du P; Li N; Xiong X; Tang S; Dai Q; Wang T; Yu M; Man M; Lam K; Baptista-Hon DT; Tai WH; Monteiro O; Ng WS; Lee UM; Liu Z; Zhang K; Li G
    MedComm (2020); 2022 Jun; 3(2):e143. PubMed ID: 35592756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
    Zaballa ME; Perez-Saez J; de Mestral C; Pullen N; Lamour J; Turelli P; Raclot C; Baysson H; Pennacchio F; Villers J; Duc J; Richard V; Dumont R; Semaani C; Loizeau AJ; Graindorge C; Lorthe E; Balavoine JF; Pittet D; Schibler M; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe KM; Kaiser L; Trono D; Stringhini S; Guessous I;
    Lancet Reg Health Eur; 2023 Jan; 24():100547. PubMed ID: 36474728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.
    Nazmunnahar ; Ahmed I; Islam MR
    Health Sci Rep; 2023 Mar; 6(3):e1127. PubMed ID: 36875932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal AR; Saif LJ; Oltz EM; Zhang B; Zhou T; Xu K; Gumina RJ; Liu SL
    Cell Rep; 2023 May; 42(5):112443. PubMed ID: 37104089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape.
    Witte L; Baharani V; Schmidt F; Wang Z; Cho A; Raspe R; Guzman-Cardozo MC; Muecksch F; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    bioRxiv; 2022 Aug; ():. PubMed ID: 36032981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages.
    Touret F; Giraud E; Bourret J; Donati F; Tran-Rajau J; Chiaravalli J; Lemoine F; Agou F; Simon-Lorière E; van der Werf S; de Lamballerie X
    iScience; 2023 Apr; 26(4):106413. PubMed ID: 36968074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
    Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
    Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fortuitous Somatic Mutations during Antibody Evolution Endow Broad Neutralization against SARS-CoV-2 Omicron Variants.
    Wu J; Chen Z; Gao Y; Wang Z; Wang J; Chiang BY; Zhou Y; Han Y; Zhan W; Xie M; Jiang W; Zhang X; Hao A; Xia A; He J; Xue S; Mayer CT; Wu F; Wang B; Zhang L; Sun L; Wang Q
    bioRxiv; 2022 Dec; ():. PubMed ID: 36561175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies.
    Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O
    bioRxiv; 2022 Nov; ():. PubMed ID: 36415455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response.
    Patel A; Kumar S; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Bajpai P; Raju DR; Edara VV; Davis-Gardner ME; Linderman S; Dixit K; Sharma P; Mantus G; Cheedarla N; Verkerke HP; Frank F; Neish AS; Roback JD; Davis CW; Wrammert J; Ahmed R; Suthar MS; Sharma A; Murali-Krishna K; Chandele A; Ortlund EA
    bioRxiv; 2022 Oct; ():. PubMed ID: 36324804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination.
    Suntronwong N; Assawakosri S; Kanokudom S; Yorsaeng R; Auphimai C; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
    Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.
    Jawad B; Adhikari P; Podgornik R; Ching WY
    Comput Biol Med; 2023 Dec; 167():107576. PubMed ID: 37871435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Saliba C; Bowen JE; Rosen LE; Culap K; Pinto D; VanBlargan LA; De Marco A; Zepeda SK; Iulio JD; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà P; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Veesler D; Snell G; Corti D
    bioRxiv; 2021 Dec; ():. PubMed ID: 34931194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.